Research Repository

Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer

Ito, Yoko and Koessler, Thibaud and Ibrahim, Ashraf EK and Rai, Sushma and Vowler, Sarah L and Abu-Amero, Sayeda and Silva, Ana-Luisa and Maia, Ana-Teresa and Huddleston, Joanna E and Uribe-Lewis, Santiago and Woodfine, Kathryn and Jagodic, Maja and Nativio, Raffaella and Dunning, Alison and Moore, Gudrun and Klenova, Elena and Bingham, Sheila and Pharoah, Paul DP and Brenton, James D and Beck, Stephan and Sandhu, Manjinder S and Murrell, Adele (2008) 'Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer.' Human Molecular Genetics, 17 (17). pp. 2633-2643. ISSN 0964-6906

[img]
Preview
Text
2633.full.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (445kB) | Preview

Abstract

The imprinted insulin-like growth factor 2 (IGF2) gene is expressed predominantly from the paternal allele. Loss of imprinting (LOI) associated with hypomethylation at the promoter proximal sequence (DMR0) of the IGF2 gene was proposed as a predisposing constitutive risk biomarker for colorectal cancer. We used pyrosequencing to assess whether IGF2 DMR0 methylation is either present constitutively prior to cancer or whether it is acquired tissue-specifically after the onset of cancer. DNA samples from tumour tissues and matched non-tumour tissues from 22 breast and 42 colorectal cancer patients as well as peripheral blood samples obtained from colorectal cancer patients [SEARCH (n = case 192, controls 96)], breast cancer patients [ABC (n = case 364, controls 96)] and the European Prospective Investigation of Cancer [EPIC-Norfolk (n = breast 228, colorectal 225, controls 895)] were analysed. The EPIC samples were collected 2-5 years prior to diagnosis of breast or colorectal cancer. IGF2 DMR0 methylation levels in tumours were lower than matched non-tumour tissue. Hypomethylation of DMR0 was detected in breast (33A%) and colorectal (80%) tumour tissues with a higher frequency than LOI indicating that methylation levels are a better indicator of cancer than LOI. In the EPIC population, the prevalence of IGF2 DMR0 hypomethylation was 9.5% and this correlated with increased age not cancer risk. Thus, IGF2 DMR0 hypomethylation occurs as an acquired tissue-specific somatic event rather than a constitutive innate epimutation. These results indicate that IGF2 DMR0 hypomethylation has diagnostic potential for colon cancer rather than value as a surrogate biomarker for constitutive LOI. © The Author 2008. Published by Oxford University Press. All rights reserved.

Item Type: Article
Uncontrolled Keywords: Humans; Breast Neoplasms; Colorectal Neoplasms; Insulin-Like Growth Factor II; Case-Control Studies; DNA Methylation; Gene Expression Regulation, Neoplastic; Genomic Imprinting; Female
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculty of Science and Health
Faculty of Science and Health > Life Sciences, School of
SWORD Depositor: Elements
Depositing User: Elements
Date Deposited: 06 Oct 2011 09:45
Last Modified: 15 Jan 2022 00:26
URI: http://repository.essex.ac.uk/id/eprint/843

Actions (login required)

View Item View Item